Scheie Eye Institute

11/26/2025

🔵 PALESTRANTE INTERNACIONAL CONFIRMADO! 🔵

🇺🇸 DR. CÉSAR A. BRICEÑO

🔹 Assistant Dean of Student Social and Professional Networks. Perelman School of Medicine at the University of Pennsylvania

🔹 Associate Professor of Clinical Ophthalmology and Dermatology. Perelman School of Medicine, University of Pennsylvania

🔹 Division Chief, Oculoplastics Service. Scheie Eye Institute, University of Pennsylvania

🔹 Co-Director. Scheie Eye Institute Thyroid Eye Disease Program. Penn Presbyterian Medical Center

Acompanhe a programação completa no nosso site e faça sua inscrição:
➡ saogeraldo2025.com.br

44º CONGRESSO DO HOSPITAL SÃO GERALDO
🗓 De 6 a 8 de novembro de 2025
🗓 Pré-Congresso - 5 de novembro de 2025
📌 Mercure Belo Horizonte Lourdes Hotel

11/24/2025

Please join the Department of Ophthalmology and the Scheie Eye Institute in celebrating and thanking some of our most recent honored speakers—Steven J. Gedde, MD; R. V. Paul Chan, MD, MSc, MBA, FACS; and Nicholas Mahoney, MD—respectively from the University of Miami Miller School of Medicine Bascom Palmer Eye Institute, the Illinois Eye and Ear Infirmary at the University of Illinois College of Medicine, and the Wilmer Eye Institute at the Johns Hopkins University School of Medicine.

11/14/2025

As we prepare to celebrate the 2025-2026 Scheie Staff Service Excellence Awardees, please join us in celebrating the 2024-2025 awardees! Additionally, congratulations to all of the incredible staff members who are celebrating career milestones and anniversaries!

11/13/2025

The Department of Ophthalmology and the Scheie Eye Institute are charting an exciting course of growth, as evidenced by our expanding geographic footprint spanning multiple new locations across both Pennsylvania and New Jersey. Scheie holds to a vision of an inclusive health system that prioritizes access—offering cutting-edge care across ever-expanding landscapes and communities. See more of Scheie soon.

11/13/2025

Penn Medicine in the News: Gene therapy is providing hope for recovering vision in people who have conditions such as leber congenital amaurosis 5, which causes a deterioration in vision related to a gene mutation. For that condition, Tomas Aleman, MD, the Irene Heinz-Given and John LaPorte Research Professor in Ophthalmology, explained the success of a new injection that puts a functioning copy of the mutated gene into affected people’s retinas, which has led to improvements in vision in daytime lighting conditions. Please watch Dr. Aleman’s feature on Good Morning America at the provided QR code or by clicking here: https://www.goodmorningamerica.com/video/127055565.

11/13/2025

10/21/2025

Please join the Department of Ophthalmology and the Scheie Eye Institute in honoring our extraordinary faculty retirees in Fiscal Year 2025: Jean Bennett, MD, PhD; Charles W. Nichols, PhD; and Juan E. Grunwald, MD. On behalf of the Scheie community, thank you to all faculty retirees for your extraordinary dedication throughout your life’s work in ophthalmology.

10/21/2025

Please join the Department of Ophthalmology and the Scheie Eye Institute in congratulating our FY2025 faculty promotions, new endowed chairs, and highlighted faculty accolades!

10/20/2025

Please join the Department of Ophthalmology and the Scheie Eye Institute in celebrating the incredible faculty members who joined our community in Fiscal Year 2025!

10/13/2025

Scheie’s educational programs prepare residents to be leaders in quality and safety long after they complete their training. Lama Al-Aswad, MD, MPH, a faculty founder of Scheie’s Resident Quality Improvement Program, explains this priority and what it means to her—emphasizing that quality is something that shapes the very “culture” of our clinician community.

10/13/2025

The Resident Research Committee—a new structured research program by Qi Cui, MD, PhD—aims to help residents sharpen their research acumen through multi-faculty mentorship in project development.

10/13/2025

The Scheie Eye Institute maintains our commitment to advancing Dry Eye Disease (DED) treatment—building upon cutting-edge research, and improving patient outcomes through conducting ongoing clinical trials, researching novel treatments, and expanding relief options for millions affected by DED.